Europe
Galapagos NV and MorphoSys AG announced today the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C.
Prof. Dr. Helga Rübsamen-Schaeff, Founding-CEO, and Dr. Holger Zimmermann, CEO of AiCuris Anti-Infective Cures GmbH are one of three teams nominated for the German President’s Award for Innovation in Science and Technology 2018
Arix Bioscience plc today announced that industry veteran Arthur Pappas has been appointed as Non-Executive Director to the Arix Board of Directors.
Rostec and the administration of the Primorsky Krai, a federal subject in the Russian Far East, have signed an agreement to establish an oncology center of proton therapy in the Primorsky region. The health clinic shall admit its first patients in 2022, its annual capacity shall be over 1000 patients.
Recipharm, a leading contract development and manufacturing organisation (CDMO) has successfully received European Medicines Verification Organisation (EMVO) approval to submit serialisation data to the European Hub.
Atlantic Healthcare plc has secured acceptance of Camligo™ as the name for the Company’s first candidate product.
ViraTherapeutics sale marks third exit from EMBL Ventures’ current fund ETF II Heidelberg, Germany, 13th Sept
Galapagos NV announced today the pricing of its U.S. public offering totaling $300 million gross proceeds of 2,575,107 new ordinary shares in the form of American Depositary Shares (“ADSs”) at $116.50 per ADS, before underwriting discounts.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
Belgium-based Galapagos NV snagged $300 million following its U.S. public offering of new ordinary shares in the form of American Depositary Shares.
PRESS RELEASES